IL-25 (IL-17E) in epithelial immunology and pathophysiology

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

卷:148

Review

Borowczyk, Julia¹  Shutova, Maria¹  Brembilla, Nicolo Costantino¹  Boehncke, Wolf-Henning^1,2 

[1] Univ Geneva, Dept Pathol & Immunol, Geneva, Switzerland

[2] Univ Hosp Geneva, Div Dermatol & Venereol, Geneva, Switzerland

关键词: IL-25;    IL-17E;    keratinocytes;    epithelial cells;    tuft cells;    atopic dermatitis;    psoriasis;    contact dermatitis;    inflammatory bowel disease;    ulcerative colitis;    Crohn disease;    chronic rhinosinusitis;    asthma;    idiopathic pulmonary fibrosis;   

DOI  :  10.1016/j.jaci.2020.12.628

来源: Elsevier

【 摘 要 】

IL-25, also known as IL-17E, is a unique cytokine of the IL-17 family. Indeed, IL-25 exclusively was shown to strongly induce expression of the cytokines associated with type 2 immunity. Although produced by several types of immune cells, such as T cells, dendritic cells, or group 2 innate lymphoid cells, a vast amount of IL-25 derives from epithelial cells. The functions of IL-25 have been actively studied in the context of physiology and pathology of various organs including skin, airways and lungs, gastrointestinal tract, and thymus. Accumulating evidence suggests that IL-25 is a barrier surfacecytokine whose expression depends on extrinsic environmental factors and when upregulated may lead to inflammatory disorders such as atopic dermatitis, psoriasis, or asthma. This review summarizes the progress of the recent years regarding the effects of IL-25 on the regulation of immune response and the balance between its homeostatic and pathogenic role in various epithelia. We revisit IL-25's general and tissue-specific mechanisms of action, mediated signaling pathways, and transcription factors activated in immune and resident cells. Finally, we discuss perspectives of the IL-25-based therapies for inflammatory disorders and compare them with the mainstream ones that target IL-17A. (J Allergy Clin Immunol 2021;148:40-52.)

【 授权许可】

Free